What is HC Wainwright’s Estimate for RGLS FY2024 Earnings?

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Equities researchers at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Regulus Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.86) per share for the year, down from their previous forecast of ($0.80). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Regulus Therapeutics’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

A number of other brokerages have also recently commented on RGLS. StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Regulus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.50 on Thursday. The business has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $1.81. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The firm has a market capitalization of $98.25 million, a price-to-earnings ratio of -1.40 and a beta of 1.63.

Hedge Funds Weigh In On Regulus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the third quarter worth $10,154,000. RA Capital Management L.P. bought a new stake in shares of Regulus Therapeutics during the 1st quarter worth $18,000,000. Vanguard Group Inc. lifted its stake in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 37,480 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at $352,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.